Expression of cancer-specific nuclear matrix protein in gastro-intestinal cancer

胃肠癌中癌症特异性核基质蛋白的表达

• 批准号: 10671163
• 负责人: ICHIKAWA Wataru
• 金额: $ 2.3万
• 依托单位: Tokyo Medical and Dental University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1998
• 资助国家: 日本
• 起止时间: 1998 至 2000
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-10671163/
• 关键词: cancer-specific antigen; nuclear matrix protein; 5-FU; gastro-intestinal cancer; モノクローナル抗体; 癌特異的

The aim of this study is to investigate the expression of cancer-specific nuclear matrix protein (NMP) in gastro-intestinal cancer. We evaluated the cancer-specific NMP (molecular weight ; 68kDa, electric point ; pH7.32) in human gastric cancer by two-dimensional gel electrophoresis, described by Fey et al.. This NMP expressed in various human cancer cell lines, including gastric and colorectal cancer. However, this protein in not specific for apoptosis. The establishment of anti-human cancer-specific NMP anti-body (Ab) was successfully performed by the conventional method using with hybridoma. The expression of this NMP was observed immunohistochemically in human materials. NMP expression was correlated with both tumor shrinkage and survival in patients treated with 5-FU based chemotherapy for metastatic tumors. This study indicates the clinical usefulness to determine the expression of cancer-specific NMP in gastro-intestinal cancer for predicting the biological behaviors.

这项研究的目的是研究胃肠癌中癌症特异性核基质蛋白（NMP）的表达。我们通过二维凝胶电泳评估了人类胃癌中癌症特异性的NMP（分子量； 68KDA，电点； PH7.32），由Fey等人描述。该NMP在包括胃癌和结肠癌在内的各种人类癌细胞系中表达。但是，该蛋白质不针对凋亡。使用杂交瘤的常规方法成功地进行了抗人类癌特异性NMP抗体（AB）的建立。在人类材料中观察到该NMP的表达。在接受5-FU化疗的转移性肿瘤治疗的患者中，NMP表达与肿瘤收缩和存活率相关。这项研究表明，在胃肠癌中确定癌症特异性NMP表达的临床有用性，以预测生物学行为。

项目成果

Hiroyuki Uetake, Wataru Ichikawa et al: "Relationship between intratumor dihydropyrimldime dehydrogenase Activity and gene expression in humory colorectal cancer"Clinical Cancer Research. 5. 2836-2839 (1999)

Hiroyuki Uetake、Wataru Ichikawa 等：“体液性结直肠癌肿瘤内二氢嘧啶脱氢酶活性与基因表达的关系”临床癌症研究。

W.Ichikawa,H.Uetake,H.Yamada, et al: "Expression of dihydoropyrimidine dehedrogenase in primary lesion predicts the anti-tumor effect in 5-FU based chemotharpy for GI tract cancer"Proc Am Soc Clin Oncol. 19. 285a (2000)

W.Ichikawa、H.Uetake、H.Yamada 等人：“原发性病变中二氢嘧啶脱毛酶的表达可预测基于 5-FU 的胃肠道癌症化疗的抗肿瘤效果”Proc Am Soc Clin Oncol。

市川度,植竹宏之,桐原正人 ほか: "抗癌剤標的酵素および代謝関連酵素発現からみた大腸癌化学療法の個性化"日本大腸肛門病会誌. 53巻・10号. 1023-1028 (2000)

Toshi Ichikawa、Hiroyuki Uetake、Masato Kirihara 等：“从抗癌药物靶酶和代谢相关酶的表达来实现结直肠癌化疗的个体化”日本结肠直肠学会杂志，第 53 卷，第 1023-1028 期。 (2000)

市川 度 他: "胃癌に特異的な核マトリックス蛋白の発現" 日本外科学会雑誌. (発表予定).

Satoshi Ichikawa 等人：“胃癌特异性核基质蛋白的表达”，日本外科学会杂志（待出版）。